Pharmaceuticals
Commercializing and developing pharmaceuticals addressing large unmet needs
What we do
Digital Therapeutics
Product portfolio of scientifically proven digital therapies
Mental illness & substance use disorders
Focusing on areas of great human suffering with wider societal implications
We Care
Shedding light on lives affected by addiction and the road to recovery
Our mission for our blog platform on which we share the stories and insights from individuals coping with addiction, recovery and mental health.
Key News
FEBRUARY 10, 2021
modia™ will be tested in patients in collaboration with ApexB.io and Magellan Rx Management
FEBRUARY 4, 2021
Great interest among institutional investors when issuing a corporate bond
FEBRUARY 1, 2021
Orexo contemplates issue of senior unsecured callable floating rate bonds
Our history
Strong history paving the way for the future. Learn more about our key milestones since we where founded in Uppsala, Sweden, in 1995.
Orexo Social
@OrexoABpubl
4 March 2021
We’re delighted to have been awarded an #EmployeeEngagement Best Practice #Award by @DecisionWise. Our employees ar… https://t.co/nBTddegfKU
@OrexoABpubl
3 March 2021
Friendly Reminder - Tomorrow on March 4th, Nikolaj Sørensen, CEO, will give a company update @redeye Investor Forum… https://t.co/rEgLCgm0Bt
@OrexoABpubl
25 February 2021
Bob DeLuca, president of #orexo US, met @PsychTimes virtually and talked about modia™ our new and upcoming digtial… https://t.co/iQ49wXb1jp
News Flow
Press Releases & News
Financial Snapshot
Group net revenues
663.6 MSEK
LTM1
Group EBITDA
19.0 MSEK
LTM1
US Pharma segment EBIT
331.2 MSEK
LTM1
Cash position
505.3 MSEK
Q4 2020
1 Last Twelve Months, Q120-Q420, for more information about financial development Link